An interventional study of Placement of WRAPSODY stent graft in Stenosis of Artery, Peripheral Arterial Disease and Iliac Artery Disease, sponsored by Merit Medical Systems, Inc.. Withdrawn. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by Merit Medical Systems, Inc. · Not applicable, Interventional, and Treatment
This is a prospective, single-center, non-randomized phase 2, first-in-iliac artery study, to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of peripheral arterial occlusive disease in symptomatic subjects with de novo or restenotic lesions in the common iliac artery (CIA) and/or external iliac artery (EIA), including lesions at the aortic bifurcation.
Approximately 30 subjects will be enrolled. Post study procedure subjects will have planned follow-up visits at 4 weeks, 24, 36 and 52 weeks, and unscheduled visits as medically necessary,
The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure. The primary clinical effectiveness endpoint is the proportion of subjects with a composite improvement of at least 1 Rutherford category and patency as evaluated by duplex ultrasound at 4 weeks after index procedure.
1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.
Browse Peripheral Arterial Disease studies →Merit Medical Systems, Inc. is the lead sponsor of 28 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This is a single arm study. All subjects will be treated with the WRAPSODY stent graft.
Device: Placement of WRAPSODY stent graft
Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
Safety endpoint of subjects free from specified adverse events
The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure.
Time frame: 4 weeks after placement of WRAPSODY stent graft
Effectiveness endpoint of subjects with improvement of Rutherford Category
The primary clinical effectiveness endpoint is the proportion of subjects with improvement of at least 1 Rutherford category within 4 weeks of the index procedure. Composite with Outcome 3.
Time frame: 4 weeks after placement of WRAPSODY stent graft
Effectiveness endpoint of subjects with patency
The primary clinical effectiveness endpoint is the proportion of subjects with patency as evaluated by duplex ultrasound at 4 weeks after index procedure. Composite with Outcome 2.
Time frame: 4 weeks after placement of WRAPSODY stent graft
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merit Medical Systems, Inc.